Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Synergistic meropenem-tobramycin combination dosage regimens against clinical hypermutable Pseudomonas aeruginosa at simulated epithelial lining fluid concentrations in a dynamic biofilm model.

Bilal H, Bergen PJ, Kim TH, Chung SE, Peleg AY, Oliver A, Nation RL, Landersdorfer CB.

Antimicrob Agents Chemother. 2019 Aug 19. pii: AAC.01293-19. doi: 10.1128/AAC.01293-19. [Epub ahead of print]

PMID:
31427301
2.

Comparable Bioavailability and Disposition of Pefloxacin in Patients with Cystic Fibrosis and Healthy Volunteers Assessed via Population Pharmacokinetics.

Bulitta JB, Jiao Y, Landersdorfer CB, Sutaria DS, Tao X, Shin E, Höhl R, Holzgrabe U, Stephan U, Sörgel F.

Pharmaceutics. 2019 Jul 10;11(7). pii: E323. doi: 10.3390/pharmaceutics11070323.

3.

Optimization of dosing regimens of intravenous colistin in patients with cystic fibrosis: What data are required?

Nation RL, Landersdorfer CB.

Pediatr Pulmonol. 2019 Oct;54(10):1497-1498. doi: 10.1002/ppul.24444. Epub 2019 Jul 8. No abstract available.

PMID:
31286687
4.

Novel Population Pharmacokinetic Approach to Explain the Differences between Cystic Fibrosis Patients and Healthy Volunteers via Protein Binding.

Shah NR, Bulitta JB, Kinzig M, Landersdorfer CB, Jiao Y, Sutaria DS, Tao X, Höhl R, Holzgrabe U, Kees F, Stephan U, Sörgel F.

Pharmaceutics. 2019 Jun 18;11(6). pii: E286. doi: 10.3390/pharmaceutics11060286.

5.

Characterization of Hypermutator Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis in Australia.

Rees VE, Deveson Lucas DS, López-Causapé C, Huang Y, Kotsimbos T, Bulitta JB, Rees MC, Barugahare A, Peleg AY, Nation RL, Oliver A, Boyce JD, Landersdorfer CB.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02538-18. doi: 10.1128/AAC.02538-18. Print 2019 Apr.

PMID:
30745381
6.

Population pharmacokinetics of intravenous colistin in pediatric patients: Implications for selection of dosage regimens.

Ooi MH, Ngu SJ, Chor YK, Li J, Landersdorfer CB, Nation RL.

Clin Infect Dis. 2019 Jan 26. doi: 10.1093/cid/ciz067. [Epub ahead of print]

PMID:
30722017
7.

The pharmacokinetics of intranasal droperidol in volunteers characterised via population modelling.

Cooper I, Landersdorfer CB, St John AG, Graudins A.

SAGE Open Med. 2018 Dec 4;6:2050312118813283. doi: 10.1177/2050312118813283. eCollection 2018.

8.

Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients.

Rees VE, Yadav R, Rogers KE, Bulitta JB, Wirth V, Oliver A, Boyce JD, Peleg AY, Nation RL, Landersdorfer CB.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e01150-18. doi: 10.1128/AAC.01150-18. Print 2018 Nov.

9.

First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers.

Jiao Y, Kim TH, Tao X, Kinzig M, Landersdorfer CB, Drescher SK, Sutaria DS, Moya B, Holzgrabe U, Sörgel F, Bulitta JB.

Eur J Pharm Sci. 2018 Oct 15;123:416-428. doi: 10.1016/j.ejps.2018.07.054. Epub 2018 Aug 1.

PMID:
30076955
10.

Population Pharmacokinetic Analyses for Ertapenem in Subjects with a Wide Range of Body Sizes.

Lakota EA, Landersdorfer CB, Zhang L, Nafziger AN, Bertino JS Jr, Bhavnani SM, Forrest A.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e00784-18. doi: 10.1128/AAC.00784-18. Print 2018 Oct.

11.

Four Decades of β-Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis.

Bulitta JB, Jiao Y, Drescher SK, Oliver A, Louie A, Moya B, Tao X, Wittau M, Tsuji BT, Zavascki AP, Shin BS, Drusano GL, Sörgel F, Landersdorfer CB.

Clin Pharmacokinet. 2019 Feb;58(2):143-156. doi: 10.1007/s40262-018-0678-x. Review.

PMID:
29936678
12.

Personalizing Polymyxin B Dosing Using an Adaptive Feedback Control Algorithm.

Lakota EA, Landersdorfer CB, Nation RL, Li J, Kaye KS, Rao GG, Forrest A.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e00483-18. doi: 10.1128/AAC.00483-18. Print 2018 Jul.

13.

Elucidation of the pharmacokinetic/pharmacodynamic determinants of fosfomycin activity against Pseudomonas aeruginosa using a dynamic in vitro model.

Bilal H, Peleg AY, McIntosh MP, Styles IK, Hirsch EB, Landersdorfer CB, Bergen PJ.

J Antimicrob Chemother. 2018 Jun 1;73(6):1570-1578. doi: 10.1093/jac/dky045.

PMID:
29506207
14.

Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling.

Yadav R, Rogers KE, Bergen PJ, Bulitta JB, Kirkpatrick CMJ, Wallis SC, Paterson DL, Nation RL, Lipman J, Roberts JA, Landersdorfer CB.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e00078-18. doi: 10.1128/AAC.00078-18. Print 2018 May.

15.

Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model.

Landersdorfer CB, Rees VE, Yadav R, Rogers KE, Kim TH, Bergen PJ, Cheah SE, Boyce JD, Peleg AY, Oliver A, Shin BS, Nation RL, Bulitta JB.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02055-17. doi: 10.1128/AAC.02055-17. Print 2018 Apr.

16.

Differences in suppression of regrowth and resistance despite similar initial bacterial killing for meropenem and piperacillin/tazobactam against Pseudomonas aeruginosa and Escherichia coli.

Bergen PJ, Bulitta JB, Sime FB, Lipman J, McGregor MJ, Millen N, Paterson DL, Kirkpatrick CMJ, Roberts JA, Landersdorfer CB.

Diagn Microbiol Infect Dis. 2018 May;91(1):69-76. doi: 10.1016/j.diagmicrobio.2017.12.019. Epub 2018 Jan 3.

PMID:
29395712
17.

Combating Carbapenem-Resistant Acinetobacter baumannii by an Optimized Imipenem-plus-Tobramycin Dosage Regimen: Prospective Validation via Hollow-Fiber Infection and Mathematical Modeling.

Landersdorfer CB, Yadav R, Rogers KE, Kim TH, Shin BS, Boyce JD, Nation RL, Bulitta JB.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02053-17. doi: 10.1128/AAC.02053-17. Print 2018 Apr.

18.

Pharmacokinetics/pharmacodynamics of systemically administered polymyxin B against Klebsiella pneumoniae in mouse thigh and lung infection models.

Landersdorfer CB, Wang J, Wirth V, Chen K, Kaye KS, Tsuji BT, Li J, Nation RL.

J Antimicrob Chemother. 2018 Feb 1;73(2):462-468. doi: 10.1093/jac/dkx409.

19.

In reply.

Wong A, Landersdorfer CB, Graudins A.

Eur J Clin Pharmacol. 2018 Feb;74(2):253. doi: 10.1007/s00228-017-2380-6. Epub 2017 Nov 16. No abstract available.

PMID:
29147804
20.

Evaluation of Pharmacokinetic/Pharmacodynamic Model-Based Optimized Combination Regimens against Multidrug-Resistant Pseudomonas aeruginosa in a Murine Thigh Infection Model by Using Humanized Dosing Schemes.

Yadav R, Bulitta JB, Wang J, Nation RL, Landersdorfer CB.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01268-17. doi: 10.1128/AAC.01268-17. Print 2017 Dec.

21.

Aminoglycoside Concentrations Required for Synergy with Carbapenems against Pseudomonas aeruginosa Determined via Mechanistic Studies and Modeling.

Yadav R, Bulitta JB, Schneider EK, Shin BS, Velkov T, Nation RL, Landersdorfer CB.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e00722-17. doi: 10.1128/AAC.00722-17. Print 2017 Dec.

22.

Characterizing the time-course of antihypertensive activity and optimal dose range of fimasartan via mechanism-based population modeling.

Bulitta JB, Paik SH, Chi YH, Kim TH, Shin S, Landersdorfer CB, Jiao Y, Yadav R, Shin BS.

Eur J Pharm Sci. 2017 Sep 30;107:32-44. doi: 10.1016/j.ejps.2017.06.008. Epub 2017 Jun 7.

PMID:
28599987
23.

Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model.

Bergen PJ, Bulitta JB, Kirkpatrick CMJ, Rogers KE, McGregor MJ, Wallis SC, Paterson DL, Nation RL, Lipman J, Roberts JA, Landersdorfer CB.

Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02642-16. doi: 10.1128/AAC.02642-16. Print 2017 May.

24.

Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling.

Yadav R, Bulitta JB, Nation RL, Landersdorfer CB.

Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e01011-16. doi: 10.1128/AAC.01011-16. Print 2017 Jan.

25.

Substantial Targeting Advantage Achieved by Pulmonary Administration of Colistin Methanesulfonate in a Large-Animal Model.

Landersdorfer CB, Nguyen TH, Lieu LT, Nguyen G, Bischof RJ, Meeusen EN, Li J, Nation RL, McIntosh MP.

Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e01934-16. doi: 10.1128/AAC.01934-16. Print 2017 Jan.

26.

Comparative pharmacodynamics of four different carbapenems in combination with polymyxin B against carbapenem-resistant Acinetobacter baumannii.

Lenhard JR, Gall JS, Bulitta JB, Thamlikitkul V, Landersdorfer CB, Forrest A, Nation RL, Li J, Tsuji BT.

Int J Antimicrob Agents. 2016 Dec;48(6):719-724. doi: 10.1016/j.ijantimicag.2016.07.024. Epub 2016 Sep 20.

27.

High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii.

Lenhard JR, Bulitta JB, Connell TD, King-Lyons N, Landersdorfer CB, Cheah SE, Thamlikitkul V, Shin BS, Rao G, Holden PN, Walsh TJ, Forrest A, Nation RL, Li J, Tsuji BT.

J Antimicrob Chemother. 2017 Jan;72(1):153-165. Epub 2016 Sep 15.

28.

Resistance suppression by high-intensity, short-duration aminoglycoside exposure against hypermutable and non-hypermutable Pseudomonas aeruginosa.

Rees VE, Bulitta JB, Oliver A, Tsuji BT, Rayner CR, Nation RL, Landersdorfer CB.

J Antimicrob Chemother. 2016 Nov;71(11):3157-3167. Epub 2016 Aug 11.

29.

Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategies.

Rao GG, Ly NS, Bulitta JB, Soon RL, San Roman MD, Holden PN, Landersdorfer CB, Nation RL, Li J, Forrest A, Tsuji BT.

J Antimicrob Chemother. 2016 Nov;71(11):3148-3156. Epub 2016 Aug 3.

30.

Lithium in Paediatric Patients with Bipolar Disorder: Implications for Selection of Dosage Regimens via Population Pharmacokinetics/Pharmacodynamics.

Landersdorfer CB, Findling RL, Frazier JA, Kafantaris V, Kirkpatrick CM.

Clin Pharmacokinet. 2017 Jan;56(1):77-90. doi: 10.1007/s40262-016-0430-3.

PMID:
27393139
31.

Effect of different renal function on antibacterial effects of piperacillin against Pseudomonas aeruginosa evaluated via the hollow-fibre infection model and mechanism-based modelling.

Bergen PJ, Bulitta JB, Kirkpatrick CM, Rogers KE, McGregor MJ, Wallis SC, Paterson DL, Lipman J, Roberts JA, Landersdorfer CB.

J Antimicrob Chemother. 2016 Sep;71(9):2509-20. doi: 10.1093/jac/dkw153. Epub 2016 May 26.

PMID:
27231278
32.

Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance.

Walsh CC, Landersdorfer CB, McIntosh MP, Peleg AY, Hirsch EB, Kirkpatrick CM, Bergen PJ.

J Antimicrob Chemother. 2016 Aug;71(8):2218-29. doi: 10.1093/jac/dkw115. Epub 2016 Apr 26.

PMID:
27118778
33.

Paradoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in Acinetobacter baumannii.

Tsuji BT, Landersdorfer CB, Lenhard JR, Cheah SE, Thamlikitkul V, Rao GG, Holden PN, Forrest A, Bulitta JB, Nation RL, Li J.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):3913-20. doi: 10.1128/AAC.02831-15. Print 2016 Jul.

34.

External manipulation of nanostructure in photoresponsive lipid depot matrix to control and predict drug release in vivo.

Fong WK, Hanley TL, Thierry B, Hawley A, Boyd BJ, Landersdorfer CB.

J Control Release. 2016 Apr 28;228:67-73. doi: 10.1016/j.jconrel.2016.02.042. Epub 2016 Feb 26.

PMID:
26924351
35.

Conjugation of 10 kDa Linear PEG onto Trastuzumab Fab' Is Sufficient to Significantly Enhance Lymphatic Exposure while Preserving in Vitro Biological Activity.

Chan LJ, Ascher DB, Yadav R, Bulitta JB, Williams CC, Porter CJ, Landersdorfer CB, Kaminskas LM.

Mol Pharm. 2016 Apr 4;13(4):1229-41. doi: 10.1021/acs.molpharmaceut.5b00749. Epub 2016 Feb 29.

PMID:
26871003
36.

Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria.

Bergen PJ, Bulman ZP, Landersdorfer CB, Smith N, Lenhard JR, Bulitta JB, Nation RL, Li J, Tsuji BT.

Infect Dis Ther. 2015 Dec;4(4):391-415. doi: 10.1007/s40121-015-0093-7. Epub 2015 Dec 8.

37.

Population Pharmacokinetic Modeling of the Enterohepatic Recirculation of Fimasartan in Rats, Dogs, and Humans.

Kim TH, Shin S, Landersdorfer CB, Chi YH, Paik SH, Myung J, Yadav R, Horkovics-Kovats S, Bulitta JB, Shin BS.

AAPS J. 2015 Sep;17(5):1210-23. doi: 10.1208/s12248-015-9764-2. Epub 2015 May 20.

38.

Population Pharmacokinetic/Pharmacodynamic Modelling of Dipeptidyl Peptidase IV Inhibitors.

Landersdorfer CB.

Clin Pharmacokinet. 2015 Jul;54(7):673-5. doi: 10.1007/s40262-015-0279-x. No abstract available.

PMID:
25940826
39.

PEGylated interferon displays differences in plasma clearance and bioavailability between male and female mice and between female immunocompetent C57Bl/6J and athymic nude mice.

Landersdorfer CB, Caliph SM, Shackleford DM, Ascher DB, Kaminskas LM.

J Pharm Sci. 2015 May;104(5):1848-55. doi: 10.1002/jps.24412. Epub 2015 Mar 5.

PMID:
25754310
40.

Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance.

Ly NS, Bulitta JB, Rao GG, Landersdorfer CB, Holden PN, Forrest A, Bergen PJ, Nation RL, Li J, Tsuji BT.

J Antimicrob Chemother. 2015 May;70(5):1434-42. doi: 10.1093/jac/dku567. Epub 2015 Feb 23.

41.

Extracorporeal clearance of colistin methanesulphonate and formed colistin in end-stage renal disease patients receiving intermittent haemodialysis: implications for dosing.

Jitmuang A, Nation RL, Koomanachai P, Chen G, Lee HJ, Wasuwattakul S, Sritippayawan S, Li J, Thamlikitkul V, Landersdorfer CB.

J Antimicrob Chemother. 2015;70(6):1804-11. doi: 10.1093/jac/dkv031. Epub 2015 Feb 18.

PMID:
25698772
42.

Novel approach to optimize synergistic carbapenem-aminoglycoside combinations against carbapenem-resistant Acinetobacter baumannii.

Yadav R, Landersdorfer CB, Nation RL, Boyce JD, Bulitta JB.

Antimicrob Agents Chemother. 2015 Apr;59(4):2286-98. doi: 10.1128/AAC.04379-14. Epub 2015 Feb 2.

43.

Two mechanisms of killing of Pseudomonas aeruginosa by tobramycin assessed at multiple inocula via mechanism-based modeling.

Bulitta JB, Ly NS, Landersdorfer CB, Wanigaratne NA, Velkov T, Yadav R, Oliver A, Martin L, Shin BS, Forrest A, Tsuji BT.

Antimicrob Agents Chemother. 2015 Apr;59(4):2315-27. doi: 10.1128/AAC.04099-14. Epub 2015 Feb 2.

44.

Colistin: how should it be dosed for the critically ill?

Landersdorfer CB, Nation RL.

Semin Respir Crit Care Med. 2015 Feb;36(1):126-35. doi: 10.1055/s-0034-1398390. Epub 2015 Feb 2. Review.

PMID:
25643276
45.

Shape does matter: short high-concentration exposure minimizes resistance emergence for fluoroquinolones in Pseudomonas aeruginosa.

Rees VE, Bulitta JB, Nation RL, Tsuji BT, Sörgel F, Landersdorfer CB.

J Antimicrob Chemother. 2015 Mar;70(3):818-26. doi: 10.1093/jac/dku437. Epub 2014 Nov 6.

PMID:
25381167
46.

Quantitative determination of absorption and first-pass metabolism of apicidin, a potent histone deacetylase inhibitor.

Shin BS, Yoo SD, Kim TH, Bulitta JB, Landersdorfer CB, Shin JC, Choi JH, Weon KY, Joo SH, Shin S.

Drug Metab Dispos. 2014 Jun;42(6):974-82. doi: 10.1124/dmd.113.056713. Epub 2014 Mar 18.

PMID:
24644298
47.

Evaluation of enrofloxacin use in koalas (Phascolarctos cinereus) via population pharmacokinetics and Monte Carlo simulation.

Black LA, Landersdorfer CB, Bulitta JB, Griffith JE, Govendir M.

J Vet Pharmacol Ther. 2014 Jun;37(3):301-11. doi: 10.1111/jvp.12091. Epub 2013 Nov 13.

PMID:
24219009
48.

Pharmacokinetic modeling and simulation of biweekly subcutaneous immunoglobulin dosing in primary immunodeficiency.

Landersdorfer CB, Bexon M, Edelman J, Rojavin M, Kirkpatrick CM, Lu J, Pfister M, Sidhu J.

Postgrad Med. 2013 Nov;125(6):53-61. doi: 10.3810/pgm.2013.11.2712.

PMID:
24200761
49.

Combination therapy for carbapenem-resistant Gram-negative bacteria.

Zavascki AP, Bulitta JB, Landersdorfer CB.

Expert Rev Anti Infect Ther. 2013 Dec;11(12):1333-53. doi: 10.1586/14787210.2013.845523. Epub 2013 Nov 6. Review.

PMID:
24191943
50.

Pharmacokinetics of colistin methanesulfonate and formed colistin in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysis.

Koomanachai P, Landersdorfer CB, Chen G, Lee HJ, Jitmuang A, Wasuwattakul S, Sritippayawan S, Li J, Nation RL, Thamlikitkul V.

Antimicrob Agents Chemother. 2014;58(1):440-6. doi: 10.1128/AAC.01741-13. Epub 2013 Nov 4.

Supplemental Content

Loading ...
Support Center